CANARIABIO INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 994 KRW | +8.52% |
|
-.--% | -80.70% |
| Mar. 29 | CANARIABIO Inc.(KOSDAQ:A016790) dropped from S&P Global BMI Index | CI |
| Jan. 24 | Quest PharmaTech Inc. Says Oregovomab Phase III Clinical Study Fails Futility Analysis | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 99,023 | 581,131 | 927,279 |
| Enterprise Value (EV) 1 | 117,889 | 698,672 | 1,033,331 |
| P/E ratio | -137 x | -1.62 x | -3.87 x |
| Yield | 3.11% | - | - |
| Capitalization / Revenue | 0.9 x | 3.68 x | 5.77 x |
| EV / Revenue | 1.07 x | 4.42 x | 6.43 x |
| EV / EBITDA | 54.8 x | -556 x | -117 x |
| EV / FCF | - | 298,438,076 x | -138,793,415 x |
| FCF Yield | - | 0% | -0% |
| Price to Book | 0.34 x | 13.7 x | -18 x |
| Nbr of stocks (in thousands) | 92,257 | 140,596 | 180,054 |
| Reference price 2 | 1,073 | 4,133 | 5,150 |
| Announcement Date | 3/29/23 | 3/29/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales 1 | 110,306 | 158,096 | 160,601 |
| EBITDA 1 | 2,152 | -1,256 | -8,853 |
| EBIT 1 | 1,250 | -2,155 | -9,795 |
| Operating Margin | 1.13% | -1.36% | -6.1% |
| Earnings before Tax (EBT) 1 | -920.3 | -281,872 | -208,712 |
| Net income 1 | -725.3 | -282,751 | -208,328 |
| Net margin | -0.66% | -178.85% | -129.72% |
| EPS 2 | -7.862 | -2,556 | -1,331 |
| Free Cash Flow | - | 2,341 | -7,445 |
| FCF margin | - | 1.48% | -4.64% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share 2 | 33.33 | - | - |
| Announcement Date | 3/29/23 | 3/29/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | 18,866 | 117,540 | 106,052 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | 8.768 x | -93.57 x | -11.98 x |
| Free Cash Flow | - | 2,341 | -7,445 |
| ROE (net income / shareholders' equity) | - | -566% | 3,775% |
| ROA (Net income/ Total Assets) | - | -0.74% | -3.1% |
| Assets 1 | - | 38,323,547 | 6,715,048 |
| Book Value Per Share 2 | 3,123 | 301.0 | -286.0 |
| Cash Flow per Share 2 | 292.0 | 48.00 | 64.60 |
| Capex 1 | 7,767 | 4,027 | 451 |
| Capex / Sales | 7.04% | 2.55% | 0.28% |
| Announcement Date | 3/29/23 | 3/29/23 | 3/21/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -80.70% | 137M | |
| +15.92% | 11.64B | |
| +0.86% | 5.85B | |
| +5.47% | 5.42B | |
| +4.59% | 4.53B | |
| -19.63% | 2.74B | |
| +3.25% | 1.92B | |
| -17.87% | 1.2B | |
| -18.21% | 965M | |
| -11.45% | 946M |
- Stock Market
- Equities
- A016790 Stock
- Financials CANARIABIO Inc.
